Gadopiclenol (2) – Elucirem®
Contrast-enhanced magnetic resonance imaging, 0 to < 2 years
Characteristics
| Start date | 01.03.2026 |
|---|---|
| Resolution | 20.08.2026 – active procedure |
| INN | Gadopiclenol |
| Brand name | Elucirem® |
| Pharm. company | Guerbet GmbH |
| G-BA Procedure ID | D-1312 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Gadopiclenol (2) | Elucirem® | Guerbet GmbH | Contrast-enhanced magnetic resonance imaging, 0 to < 2 years | n.d. | active procedure | |
| Gadopiclenol (1) | Elucirem® | Guerbet GmbH | Contrast-enhanced magnetic resonance imaging, ≥ 2 years | 2,900,000–3,300,000 | 100% additional benefit not proven |
<< List of all resolutions